Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 17Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neuroblastoma 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Renal Cell 4Burkitt Lymphoma 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 11X-Rays 8Biopsy 8Temozolomide 7Phantoms, Imaging 7Radiotherapy 6Nuclear Medicine Department, Hospital 6Bevacizumab 6erdafitinib 4Surgical Procedures, Operative 4Radiation 4Nivolumab 4Carmustine 4Carboplatin 4ulixertinib 3temsirolimus 3palbociclib 3olaparib 3larotrectinib 3Vorinostat 3Sunitinib 3IL13-PE38 3Chemotherapy, Adjuvant 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioma × Ipilimumab × Clear all
NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡